REFERENCES
Kroon BBR. Regional isolated perfusion in melanoma of the limbs: Accomplishments, unsolved problems, future. Eur J Surg Oncol 1988; 14: 101–10.
Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997; 132: 903–7.
Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumour necrosis factor alpha in combination with interferon gamma and melphalan in isolated limb perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52–60.
Daryanani D, Komdeur R, Ter Veen J, Nijhuis PH, Piers DA, Hoekstra HJ. Continuous leakage measurement during hyperthermic isolated limb perfusion. Ann Surg Oncol 2001; 8: 566–572.
Koops HS, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomised phase II trial. J Clin Oncol 1998; 16: 2906–12.
Vrouenraets BC, Klaase JM, Nieweg OE, Kroon BB. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol 1998; 14: 224–31.
Karakousis CP, Kanter PM, Park HC, et al. Tourniquet infusion versus hyperthermic perfusion. Cancer 1982; 49: 850–8.
Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion. Semin Surg Oncol 1998; 14: 238–47.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Thompson, J.F., de Wilt, J.H.W. Isolated Limb Perfusion in the Management of Patients With Recurrent Limb Melanoma: An Important but Limited Role. Ann Surg Oncol 8, 564–565 (2001). https://doi.org/10.1007/s10434-001-0564-9
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10434-001-0564-9